Literature DB >> 466765

Measurement of aspartate aminotransferase activity: effects of oxamate.

R Rej.   

Abstract

Oxamate, a potent inhibitor of lactate dehydrogenase, is shown also to inhibit aspartate aminotransferase activity, both in human serum and in purified isoenzymes of human origin. The inhibition was competitive with respect to 2-oxoglutarate for both isoenzymes. The apparent Ki was 29 mmol/L for the cytoplasmic enzyme and 17 mmol/L for the mitochondrial enzyme. Noncompetitive inhibition was found between oxamate and aspartate. At saturating concentrations of substrate (2-oxoglutarate greater than or equal to 15 mmol/L, L-aspartate greater than or equal 150 mmol/L) oxamate inhibited the mitochondrial enzyme but had less effect on the cytoplasmic isoenzyme. Oxamate at 40 mmol/L inhibited the enzyme in serum by 11 and 9% in assays containing 2-oxoglutarate at 6.7 and 15 mmol/L, respectively. This concentration of oxamate inhibited enzyme activity in serum by 5% more than did the same concentration of Cl- (itself an inhibitor). Oxamate (less than or equal to 30 mmol/L) had no measurable effect on the stability or activity of porcine malate dehydrogenase. Until the effects of its inhibitory properties are considered, addition of oxamate to suppress lactate dehydrogenase-mediated side reactions in the assay of aspartate aminotransferase cannot be recommended.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 466765

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

Review 1.  Small mitochondria-targeting molecules as anti-cancer agents.

Authors:  Feng Wang; Marcia A Ogasawara; Peng Huang
Journal:  Mol Aspects Med       Date:  2009-12-06

Review 2.  Lactate metabolism: historical context, prior misinterpretations, and current understanding.

Authors:  Brian S Ferguson; Matthew J Rogatzki; Matthew L Goodwin; Daniel A Kane; Zachary Rightmire; L Bruce Gladden
Journal:  Eur J Appl Physiol       Date:  2018-01-10       Impact factor: 3.078

3.  Genome-wide association study identifies genetic variants in GOT1 determining serum aspartate aminotransferase levels.

Authors:  Haiqing Shen; Coleen Damcott; Scott R Shuldiner; Sumbul Chai; Rongze Yang; Hong Hu; Quince Gibson; Kathleen A Ryan; Braxton D Mitchell; Da-Wei Gong
Journal:  J Hum Genet       Date:  2011-09-08       Impact factor: 3.172

4.  Oxidative phosphorylation, not glycolysis, powers presynaptic and postsynaptic mechanisms underlying brain information processing.

Authors:  Catherine N Hall; Miriam C Klein-Flügge; Clare Howarth; David Attwell
Journal:  J Neurosci       Date:  2012-06-27       Impact factor: 6.167

5.  The Prognostic Value of Multiple Systemic Inflammatory Biomarkers in Preoperative Patients With Non-small Cell Lung Cancer.

Authors:  Kai Wang; Qidi Zhao; Tao Yan; Deyu Guo; Jichang Liu; Guanghui Wang; Jiajun Du
Journal:  Front Surg       Date:  2022-04-04

6.  Targeting aspartate aminotransferase in breast cancer.

Authors:  Joshua Marshall Thornburg; Kristin K Nelson; Brian F Clem; Andrew N Lane; Sengodagounder Arumugam; Allan Simmons; John W Eaton; Sucheta Telang; Jason Chesney
Journal:  Breast Cancer Res       Date:  2008-10-15       Impact factor: 6.466

7.  D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH.

Authors:  K Oizel; C Gratas; A Nadaradjane; L Oliver; F M Vallette; C Pecqueur
Journal:  Cell Death Dis       Date:  2015-03-26       Impact factor: 9.685

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.